Y-mAbs reported preliminary estimated unaudited full year 2024 total net revenue of approximately $88 million, within the Company’s previously announced guidance range of between $87 million and $91 million, and preliminary estimated unaudited cash, cash equivalents and marketable securities as of December 31, 2024 of approximately $67 million, with preliminary estimated total cash investment for the full year 2024 of approximately $11 million, which is below the Company’s guidance range of between $15 million and $20 million.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
- Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
- Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential
- Y-mAbs Therapeutics initiated with a Buy at Brookline
- Y-mAbs Therapeutics initiated with an Outperform at Oppenheimer